Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-065101

Chief Business Development Off sold 417 shares at $59.14 ($24,661)

  • Chief Business Development Off acquired 417 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-12-21 Option exercise +417 $6.27 $2,615 417 D
BENZENO SHARON Chief Business Development Off 2020-12-21 Sale −417 $59.14 $24,661 0 D
Derivatives
BENZENO SHARON Chief Business Development Off 2020-12-21 Option exercise · Stock Option (Right to Buy) −417 1,667 D
Open-market sales · 417 sh · avg $59.14 · $24,661
Loading xslF345X03/doc4.xml…